API

A steroid is a type of organic compound that contains...

read more...

Pharma Intermediate

Pharmaceuticals refer to the drugs and medicines...

read more...

Speciality Chemicals

Specialty chemicals are those chemicals which is produced...

read more...

Products Under Devp.

New Products Under Development In response...

read more...

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH 2009
(Rs. In Lacs)
PARTICULARS For the Quarter Ended For the Quarter Ended For the Year ended For the Year ended Consolidated For theYear ended
31st
Mar 2009
31st
Mar 2008
31st
Mar 2009
31st
Mar 2008
31st
Mar
2009
31st
Mar
2008
1. (a) (Net) Sales / Income from operations 10,680 11,005 37,650 31,073 38,212 31,236
(b) Other Operating Income - - - - - -
2. Expenditure
(a). (Increase) / Decrease in stock in trade 1,212 1,004 695 (924) 889 (1,038)
(b). Consumption of raw materials. 4,651 4,776 21,077 18,259 21,388 18,541
(c). Purchase of Traded Goods 1,311 2,322 3,443 3,892 2,522 3,084
(d). Employees cost 336 275 1,114 980 1,200 1,054
(e). Depreciation 319 252 1,104 963 1,448 1,302
(f). Other expenditure 1,534 1,595 5,648 5,119 5,779 5,180
(g). Total Expenditure 9,363 10,224 33,081 28,289 33,225 28,123
3. Profit from Operating before Other Income 1,317 781 4,570 2,783 4,987 3,112
4. Other Income 1 112 17 184 52 185
5. Profit before Interest & Exceptional Items 1,318 893 4,587 2,967 5,040 3,297
6. Interest 508 582 2,272 1,184 2,435 1,288
7. Profit after Interest but before Exceptional Items 810 311 2,315 1,783 2,604 2,009
8. Exceptional Items - - - - - -
9. Profit from Ordinary Activities before Tax 810 311 2,315 1,783 2,604 2,009
10. Tax Expenses (Includes) 354 124 810 476 847 528
Provision for Taxation 272 55 540 230 580 256
Provision for FBT 4 5 15 16 16 17
Provision for Deffered Taxation 78 65 255 230 251 256
11. Net profit from ordinary Activities after Tax 456 187 1,505 1,307 1,757 1,481
12. Extraodinary Item (net of tax expenses )
13. Net Profit for the period 456 187 1,505 1,307 1,757 1,481
Less :
( a) Minority Interest - - - - 86 73
( b) Adjustments on Consolidation - - - - 19 12
( c) Share of Loss in Associate - - - - 56 23
Profit After Consolidation adjustments 456 187 1,505 1,307 1,597 1,374
14. Paid-up Equity Share Capital of Rs.10/- each. 1,171 1,171 1,171 1,171 1,171 1,171
15. Reserves & Surplus (excluding revaluation reserves) - - 10,827 9,734 11,153 9,982
16. Basic E P S (in Rs.) 3.90 1.60 12.85 11.17 13.64 11.73
17. Public Shareholding
Number of Shares 5495949 6045866 5495949 6045866 5495949 6045866
Percentage of Total Shareholding 46.94 51.64 46.94 51.64 46.94 51.64
18. Promoters & Promoter Group Shareholding**
a) Pledged/Encumbered
- Number of Shares NIL N.A NIL N.A NIL N.A
-Percentage of shares( as a percentage of the total shareholding of promoter and promoter group) NIL N.A NIL N.A NIL N.A
-Percentage of shares( as a percentage of total sharecapital of the Company) NIL N.A NIL N.A NIL N.A
b) Non-encumbered
- Number of Shares 6212601 N.A 6212601 N.A 6212601 N.A
-Percentage of shares( as a percentage of total shareholding of promoter and promoter group) 100 N.A 100 N.A 100 N.A
-Percentage of shares (as a percentage of total sharecapital of the Company) 53.06 N.A 53.06 N.A 53.06 N.A

Notes :

1. The above results, reviewed by the Audit Committee, have been taken on record by the Board of Directors at their meeting held on 20th May 2009.

2. Company is operating as a Single Segment Company, engaged in pharmaceuticals business hence, the disclosure requirement as per AS - 17 'Segment Reporting' is not attracted.

3. The figures of the previous periods have been regrouped and rearranged wherever necessary.

4. Number of Investors complaints (i) pending at the beginning of quarter 1 (ii) received during the quarter : 10 (Iii) redressed : 10 (iv) pending at the end of the quarter : 1.

For and on behalf of the Board

FOR AARTI DRUGS LIMITED

Sd/-

Place : Mumbai Harshit M Savla

Date : 30th Oct, 2009 (Jt. Managing Director)

 

Resource Download

Annual Report
Click here to download
annual report
Investor Presentation
Click here to download
Presentation

Copyright © 2010 Aarti Drugs Ltd. All Rights Reserved
Website Developed by : Sri Hema Infotech